Hints and tips:
...Ablynx’s main asset is caplacizumab, a treatment for the rare bleeding disorder acquired Thombotic Thrombocytopenic Purpura (aTTP), and Novo Nordisk said a deal offered a “compelling opportunity” to combine...
...Ablynx’s main asset is Caplacizumab, a treatment for the rare blood disorder acquired thrombotic thrombocytopenic purpura (aTTP), and Novo said a deal offered a “compelling opportunity” to bring the drug...
International Edition